[go: up one dir, main page]

BG64641B1 - Използване на производни на каптотецин с намалена стомашно-чревна токсичност - Google Patents

Използване на производни на каптотецин с намалена стомашно-чревна токсичност Download PDF

Info

Publication number
BG64641B1
BG64641B1 BG105216A BG10521601A BG64641B1 BG 64641 B1 BG64641 B1 BG 64641B1 BG 105216 A BG105216 A BG 105216A BG 10521601 A BG10521601 A BG 10521601A BG 64641 B1 BG64641 B1 BG 64641B1
Authority
BG
Bulgaria
Prior art keywords
cpt
sodium chloride
days
administration
day
Prior art date
Application number
BG105216A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG105216A (en
Inventor
Herve Toutain
Magali Guffroy
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9810043A external-priority patent/FR2782009B1/fr
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of BG105216A publication Critical patent/BG105216A/xx
Publication of BG64641B1 publication Critical patent/BG64641B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
BG105216A 1998-08-05 2001-02-05 Използване на производни на каптотецин с намалена стомашно-чревна токсичност BG64641B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810043A FR2782009B1 (fr) 1998-08-05 1998-08-05 Utilisation de derives de la comptothecine, avec une toxicite gastro-intestinale reduite
US9631898P 1998-08-12 1998-08-12

Publications (2)

Publication Number Publication Date
BG105216A BG105216A (en) 2001-10-31
BG64641B1 true BG64641B1 (bg) 2005-10-31

Family

ID=26234482

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105216A BG64641B1 (bg) 1998-08-05 2001-02-05 Използване на производни на каптотецин с намалена стомашно-чревна токсичност

Country Status (24)

Country Link
US (1) US6476043B1 (et)
EP (1) EP1102594B1 (et)
JP (1) JP2002522392A (et)
KR (1) KR20010072228A (et)
AT (1) ATE217531T1 (et)
AU (1) AU771195B2 (et)
BG (1) BG64641B1 (et)
CA (1) CA2340020A1 (et)
CZ (1) CZ295775B6 (et)
DE (1) DE69901506T2 (et)
DK (1) DK1102594T3 (et)
EA (1) EA002917B1 (et)
EE (1) EE04264B1 (et)
ES (1) ES2176009T3 (et)
GE (1) GEP20043254B (et)
HU (1) HUP0103314A3 (et)
ID (1) ID27253A (et)
IL (1) IL141232A0 (et)
NO (1) NO20010454L (et)
NZ (1) NZ509859A (et)
PT (1) PT1102594E (et)
SK (1) SK1732001A3 (et)
TR (1) TR200100331T2 (et)
WO (1) WO2000007605A1 (et)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069390A2 (en) 1999-05-17 2000-11-23 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
US20080242691A1 (en) * 2004-02-13 2008-10-02 Kabushiki Kaisha Yakult Honsha Aqueous Solution Preparation Containing Camptothecins
US20050197355A1 (en) * 2004-03-02 2005-09-08 Henegar Kevin E. Compounds useful in preparing camptothecin derivatives
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
JP2006151950A (ja) * 2004-11-05 2006-06-15 Oto Corporation:Kk 納豆菌培養エキス含有製剤及び納豆菌培養エキスの保存方法
PL1846412T3 (pl) * 2005-02-07 2010-03-31 Fermion Oy Sposób wytwarzania 7-etylo-10-hydroksykamptotecyny
EP1928883B1 (en) * 2005-02-08 2013-10-30 Fermion Oy Process for the preparation of irinotecan hydrochloride
JP5133703B2 (ja) * 2005-02-08 2013-01-30 フェルミオン オサケ ユキチュア ［１，４’］ビピペリジニル−１’−カルボニルクロリドまたはその塩酸塩の製造方法
US7994186B2 (en) * 2005-04-18 2011-08-09 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
KR20080039344A (ko) 2005-07-14 2008-05-07 웰스테트 바이올로직스 코포레이션 바이러스, 플루오로피리미딘 및 캄토테신을 이용한 암치료방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056692A1 (en) * 1981-01-09 1982-07-28 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives and process for their preparation
EP0088642A2 (en) * 1982-03-10 1983-09-14 Kabushiki Kaisha Yakult Honsha New camptothecin derivatives and process for their preparation
EP0137145A1 (en) * 1983-07-14 1985-04-17 Kabushiki Kaisha Yakult Honsha New camptothecin derivatives and process for preparing same
EP0296612A1 (en) * 1987-06-25 1988-12-28 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
EP0321122A2 (en) * 1987-12-01 1989-06-21 Smithkline Beecham Corporation Water soluble camptothecin analogs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284579A (en) * 1979-07-17 1981-08-18 The United States Of America As Represented By The Of The Department Of Health & Human Services (N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt
CH663353A5 (de) * 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
IT1247937B (it) * 1991-05-16 1995-01-05 Ist Naz Ric Sul Cancro Associazione farmaceutica ad attivita' antineoplastica
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
AU3684395A (en) 1994-10-06 1996-05-02 Leon T. Atlas Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056692A1 (en) * 1981-01-09 1982-07-28 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives and process for their preparation
EP0088642A2 (en) * 1982-03-10 1983-09-14 Kabushiki Kaisha Yakult Honsha New camptothecin derivatives and process for their preparation
EP0137145A1 (en) * 1983-07-14 1985-04-17 Kabushiki Kaisha Yakult Honsha New camptothecin derivatives and process for preparing same
EP0296612A1 (en) * 1987-06-25 1988-12-28 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
EP0321122A2 (en) * 1987-12-01 1989-06-21 Smithkline Beecham Corporation Water soluble camptothecin analogs

Also Published As

Publication number Publication date
JP2002522392A (ja) 2002-07-23
GEP20043254B (en) 2004-06-25
ATE217531T1 (de) 2002-06-15
KR20010072228A (ko) 2001-07-31
NO20010454D0 (no) 2001-01-26
EA002917B1 (ru) 2002-10-31
HUP0103314A2 (hu) 2002-01-28
CA2340020A1 (fr) 2000-02-17
BG105216A (en) 2001-10-31
EE200100066A (et) 2002-06-17
CZ2001382A3 (en) 2001-05-16
NZ509859A (en) 2003-09-26
HUP0103314A3 (en) 2002-07-29
EP1102594A1 (fr) 2001-05-30
DE69901506D1 (de) 2002-06-20
CZ295775B6 (cs) 2005-11-16
IL141232A0 (en) 2002-03-10
WO2000007605A1 (fr) 2000-02-17
ES2176009T3 (es) 2002-11-16
AU5168799A (en) 2000-02-28
US6476043B1 (en) 2002-11-05
EA200100214A1 (ru) 2001-08-27
EP1102594B1 (fr) 2002-05-15
NO20010454L (no) 2001-01-26
AU771195B2 (en) 2004-03-18
ID27253A (id) 2001-03-22
TR200100331T2 (tr) 2001-07-23
DE69901506T2 (de) 2002-11-28
DK1102594T3 (da) 2002-08-26
PT1102594E (pt) 2002-10-31
EE04264B1 (et) 2004-04-15
SK1732001A3 (en) 2001-06-11

Similar Documents

Publication Publication Date Title
EP1104297B1 (en) Compositions for the treatment of chronic lymphocytic leukemia
US20040110828A1 (en) Tetrahydrocannabinol compositions and methods of manufacture and use thereof
ES2287495T3 (es) Forma polimorfa cristalina de clorhidrato de irinotecan.
BG64641B1 (bg) Използване на производни на каптотецин с намалена стомашно-чревна токсичност
KR20040106422A (ko) 간암 및 다른 암 질병 치료용 에포틸론 유도체
KR0143410B1 (ko) B형 비루스성 간염치료용 제약학적 조성물
JP2738979B2 (ja) 非小細胞肺癌の治療
KR20030082544A (ko) 캄프토테신과 스틸벤 유도체를 포함하는 암 치료용 배합물
RU2358731C2 (ru) Cci-779 для лечения лимфомы из мантийных клеток
MXPA01000689A (en) Use of camptothecin derivatives, with reduced gastrointestinal toxicity
JPH06505487A (ja) 食道癌の治療用医薬組成物
EP1707568B1 (en) A pharmaceutical composition for use in the treatment of ovarian cancer in a human afflicted therewith
EP1694242A1 (en) Pharmaceutical formulations of camptothecins and process for making same
CN1144592C (zh) 低胃肠毒性喜树碱衍生物的应用
US20060094692A1 (en) Pharmaceutical formulations of camptothecins and process for making same
EP1671631A2 (en) Compositions for the treatment of chronic lymphocytic leukemia
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法
HK1095517A (en) Pharmaceutical composition for the treatment of ovarian cancer
HK1099549A (en) A pharmaceutical composition for use in the treatment of ovarian cancer in a human afflicted therewith
HK1012265B (en) Use of topotecan in the manufacture of a medicament for use in the treatment of ovarian cancer